NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 175)
Posted On: 06/28/2022 4:16:14 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Adelia Announce Achievement of Milestone
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when the company acquired Adelia. Reaching the milestone means that an estimated 37,366.2 class B common shares in Cybin will be issued to Adelia shareholders; the issuance of the shares represents the approximately $217,465 that Cybin agreed to pay if the key milestone was achieved. Adelia is a subsidiary of Cybin that is focused on developing medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, a biotechnology company focused on progressing Psychedelics to Therapeutics(TM), and its wholly controlled subsidiary Adelia Therapeutics Inc., have announced the achievement of a key milestone. The milestone is identified as Y2, Q3 in the contribution agreement created between Adelia and Cybin when the company acquired Adelia. Reaching the milestone means that an estimated 37,366.2 class B common shares in Cybin will be issued to Adelia shareholders; the issuance of the shares represents the approximately $217,465 that Cybin agreed to pay if the key milestone was achieved. Adelia is a subsidiary of Cybin that is focused on developing medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼